Overview

To Evaluate the Safety, Tolerability, and Pharmacokinetics Profile in Healthy Chinese Volunteers of TG-2349

Status:
Completed
Trial end date:
2017-08-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) profile of different doses of TG-2349 (Furaprevir capsule) in healthy Chinese volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
Collaborator:
R&G Pharma Studies Co.,Ltd.